Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for Overactive Bladder in Parkinson's Disease
NCT05997043Phase 1Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of botulinum toxin type A in overactive bladder (OAB) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Symptom score of overactive bladder at 3 months. Started Aug 2023; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05997043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997043.